AAAAAA

   
Results: 1-10 |
Results: 10
The complex of recombinant human insulin like growth factor-I (rhIGF-I) and its binding protein-5 (IGFBP-5) induces local bone formation in murine calvariae and in rat cortical bone after local or systemic administration
Authors: Bauss, F Lang, K Dony, C Kling, L
Citation: F. Bauss et al., The complex of recombinant human insulin like growth factor-I (rhIGF-I) and its binding protein-5 (IGFBP-5) induces local bone formation in murine calvariae and in rat cortical bone after local or systemic administration, GROWTH H I, 11(1), 2001, pp. 1-9
Association between histomorphometry and biochemical markers of bone turnover in a longitudinal rat model of parathyroid hormone-related peptide (PTHrP)-mediated tumor osteolysis
Authors: Juraschek, M Seibel, MJ Woitge, HW Krempien, B Bauss, F
Citation: M. Juraschek et al., Association between histomorphometry and biochemical markers of bone turnover in a longitudinal rat model of parathyroid hormone-related peptide (PTHrP)-mediated tumor osteolysis, BONE, 26(5), 2000, pp. 475-483
Impaired bone metabolism following augmentation cystoplasties in growing rats
Authors: Brkovic, D Seibel, M Kissling, C Dorsam, J Wiesel, M Staehler, G Bauss, F
Citation: D. Brkovic et al., Impaired bone metabolism following augmentation cystoplasties in growing rats, EUR UROL, 38(6), 2000, pp. 766-773
Treatment with ibandronate preserves bone in experimental tumour-induced bone loss
Authors: Kurth, AHA Kim, SZ Sedlmeyer, I Hovy, L Bauss, F
Citation: Aha. Kurth et al., Treatment with ibandronate preserves bone in experimental tumour-induced bone loss, J BONE-BR V, 82B(1), 2000, pp. 126-130
Short-term administration of the bisphosphonate ibandronate increases bonevolume and prevents hyperparathyroid bone changes in mild experimental renal failure
Authors: Geng, Z Monier-Faugere, MC Bauss, F Malluche, HH
Citation: Z. Geng et al., Short-term administration of the bisphosphonate ibandronate increases bonevolume and prevents hyperparathyroid bone changes in mild experimental renal failure, CLIN NEPHR, 54(1), 2000, pp. 45-53
Anti-osteolytic therapy preserves trabecular architecture and mechanical properties of bone in tumor osteolysis.
Authors: Kurth, AA Kim, SZ Bauss, F Muller, R Hovy, L
Citation: Aa. Kurth et al., Anti-osteolytic therapy preserves trabecular architecture and mechanical properties of bone in tumor osteolysis., Z ORTHOP GR, 138(2), 2000, pp. 146-151
Bisphosphonates and novel related structural classes for bone resorption disorders
Authors: Esswein, A Bauss, F Muehlbauer, R Guenther, H Bosies, E
Citation: A. Esswein et al., Bisphosphonates and novel related structural classes for bone resorption disorders, PHOSPHOR SU, 146, 1999, pp. 13-16
Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: Effects on bone morphometry and mineral properties
Authors: Monier-Faugere, MC Geng, ZP Paschalis, EP Qi, QL Arnala, I Bauss, F Boskey, AL Malluche, HH
Citation: Mc. Monier-faugere et al., Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: Effects on bone morphometry and mineral properties, J BONE MIN, 14(10), 1999, pp. 1768-1778
Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease
Authors: Dallas, SL Garrett, IR Oyajobi, BO Dallas, MR Boyce, BF Bauss, F Radl, J Mundy, GR
Citation: Sl. Dallas et al., Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease, BLOOD, 93(5), 1999, pp. 1697-1706
Lifelong administration of high doses of ibandronate increases bone mass and maintains bone quality of lumbar vertebrae in rats
Authors: Lalla, S Hothorn, LA Haag, N Bader, R Bauss, F
Citation: S. Lalla et al., Lifelong administration of high doses of ibandronate increases bone mass and maintains bone quality of lumbar vertebrae in rats, OSTEOPOR IN, 8(2), 1998, pp. 97-103
Risultati: 1-10 |